Global X China Biotech Innovation ETF (CHB)

NASDAQ: CHB · IEX Real-Time Price · USD
-0.27 (-2.77%)
At close: Dec 5, 2022 10:02 AM
-0.02 (-0.16%)
After-hours: Dec 5, 2022 4:15 PM EST
Assets $2.63M
NAV $9.74
Expense Ratio 0.65%
PE Ratio 30.84
Shares Out 270,000
Dividend (ttm) $0.02
Dividend Yield 0.21%
Ex-Dividend Date Dec 29, 2022
1-Year Return -38.24%
Volume 2,223
Open 9.66
Previous Close 9.74
Day's Range 9.42 - 9.66
52-Week Low 8.02
52-Week High 15.64
Beta 0.12
Holdings 31
Inception Date Sep 22, 2020

About CHB

The Global X China Biotech Innovation ETF (CHB) is an exchange-traded fund that is based on the Solactive China Biotech Innovation index. The fund tracks a market-cap weighted index of Chinese companies that are involved in the biotechnology industry. CHB was launched on Sep 22, 2020 and is managed by Global X.

Asset Class Equity
Region Asia-Pacific
Stock Exchange NASDAQ
Ticker Symbol CHB
Issuer Website Global X
Index Tracked Solactive China Biotech Innovation

Top 10 Holdings

61.53% of assets
Name Symbol Weight
CHANGCHUN HIGH-A 000661.SZ 7.05%
CHONGQING ZHIF-A 300122.SZ 6.95%
Zai Lab Limited ZLAB 5.35%
HUALAN BIOLOGI-A 002007.SZ 4.35%
SHANGHAI RAAS -A 002252.SZ 4.32%
BEIJING TIAN-A 600161.SS 4.27%
DAAN GENE CO LTD-A 002030.SZ 4.05%
View More Holdings


Ex-Dividend Amount Pay Date
Jun 29, 2022 $0.01989 Jul 8, 2022
Full Dividend History


Capitalize on Biotech Growth in China With This ETF

After a rough 2021 that featured the Evergrande Crisis and heavy regulatory measures on technology to keep monopolistic moves in check, investors are eyeing opportunities in China. One of the sectors of...

4 months ago - ETF Trends

This Week's Top Performing ETFs: 06/19/2022

Top Performing Unleveraged ETFs Last Week These were last week's top-performing ETFs. We've excluded funds that use leverage or make inverse bets on their underlying assets.

5 months ago - ETF Trends

Innovation Should Help Fuel Growth in This China Biotech ETF

Growth opportunities are abounding in Chinese biotech. A confluence of regulatory reforms, industry talent, and the re-opening of the country's capital markets have helped propel China's biotech industr...

8 months ago - ETF Trends

5 Top-Performing ETFs of Last Week

Wall Street was downbeat last week on inflationary concerns and some downbeat economic data points.

Other symbols: CHIHEPUKURE
1 year ago - Zacks Investment Research

The CHB ETF: China's Burgeoning Biotech Sector

As China continues to lead the global recovery, one area to keep a close eye on is biotechnology and the Global X China Biotech Innovation ETF (CHB). CHB seeks to provide investment results that corresp...

1 year ago - ETF Trends

Are Healthcare ETFs Poised for a Comeback?

Decent earnings growth picture and valuation as well as solid deals activities have been favoring healthcare sector at the current level.

1 year ago - Zacks Investment Research

ETF Odds & Ends: First Mutual Fund Conversion

Plus, iShares lowered expense ratios on two of its ETFs.

1 year ago - ETFcom

3 Biotech Stocks With Eye-Catching Pipelines

Investing in biotech stocks may feel daunting to many investors, but these three stocks deserve to be on your watchlist. The post 3 Biotech Stocks With Eye-Catching Pipelines appeared first on InvestorP...

Other symbols: ABBVRPRX
2 years ago - InvestorPlace

China's Quest for a Covid-19 Vaccine Could Help Boost This ETF

All around the world, economic superpowers are vying to be the first to develop a vaccine for Covid-19. China is an obvious contender given that the country was the epicenter of the virus and their succ...

2 years ago - ETF Trends